Online harms place substantial cost on Canada’s health and justice systems, report says - The Globe and Mail

An update from Ramsay Health Care ( (AU:RHC) ) is now available. Challenger Limited, an Australian financial services group, has filed a notice with the ASX indicating it has ceased to be a substantial shareholder in Ramsay Health Care. The change reflects a reduction in Challenger’s voting interest below the substantial holding threshold, altering the composition of Ramsay’s institutional investor base and potentially signaling a reallocation of capital by Challenger. The notice, lodged by Challenger’s company secretary, formally records the cessation of substantial holder status and covers Challenger and its associated entities. While specific transaction details were not disclosed in the text provided, the move underscores ongoing shifts in share ownership that may influence Ramsay’s market dynamics and governance landscape. The most recent analyst rating on (AU:RHC) stock is a Hold with a A$49.39 price target. To see the full list of analyst forecasts on Ramsay Health Care stock, see the AU:RHC Stock Forecast page.

Bioengineer.org news storyFor people living with HIV, modern antiretroviral therapy can suppress the virus to levels below what standard laboratory tests can detect. Yet some patients on long-term treatment experience a curious phenomenon: a single test result showing a small, transient amount of virus in the blood, followed by an immediate return to undetectable levels. These events, known as viral blips, have puzzled clinicians and researchers for years, raising questions about whether they represent harmless statistical noise, brief bursts of viral production from hidden reservoirs, or early warnings of impending treatment failure. A new nationwide Swedish study, published in BMC Infectious Diseases, offers one of the most comprehensive answers to date. Drawing on the Swedish national InfCareHIV cohort, researchers analyzed data from 4,210 treatment-naïve adults who began antiretroviral therapy from 1 January 2007 onward, with follow-up data extracted through 30 September 2020. The median observation time was 5.5 years, with some individuals followed for as long as 13.7 years.

European Medical Journal news storyPeople living with HIV may experience subtle changes in heart muscle function even when conventional measures of cardiac performance remain normal, according to findings from a systematic review and meta-analysis. Researchers identified significantly impaired global longitudinal strain (GLS) among people with HIV compared with HIV-uninfected individuals, despite preserved left ventricular ejection fraction (LVEF) in both groups. The findings suggest that speckle-tracking echocardiography (STE) could provide additional information about early myocardial dysfunction in this population. Read the full news story here.

Among cancer patients, the high financial cost of cancer care is a prevalent problem. This financial burden is also associated with potentially harmful behavioral strategies that patients might use to cope with costs, such as delaying or forgoing treatment and skipping medications. Collectively, researchers refer to this impact as financial toxicity.